REACT
Research type
Research Study
Full title
A randomised study of interferon-free treatment for recently acquired hepatitis C in people who inject drugs and people with HIV coinfection (REACT)
IRAS ID
195890
Contact name
Sanjay Bhagani
Contact email
Sponsor organisation
The University of New South Wales Australia
Eudract number
2015-004243-39
Clinicaltrials.gov Identifier
Duration of Study in the UK
3 years, 10 months, 28 days
Research summary
The aim of the study is to determine if treatment for recent hepatitis C virus (HCV) infection (with or without HIV coinfection) can be shortened when treating with the interferon-free therapy sofosbuvir/velpatasvir (SOF/VEL).
SOF/VEL is a new treatment for hepatitis C called direct acting antiviral which targets the hepatitis C virus replication cycle and has been shown in phase II studies in chronic HCV to be highly effective [SVR12 (cure rate) >95%] when given for 12 weeks.
Data has shown that treatment can be shortened when treating recently acquired HCV with interferon containing treatments. It is not known whether treatment with SOF/VEL can be shortened.
This study aims to see if treatment for 6 weeks with SOF/VEL is equivalent to treatment for 12 weeks with SOF/VEL in patients with recently acquired hepatitis C infection.REC name
London - City & East Research Ethics Committee
REC reference
16/LO/1905
Date of REC Opinion
13 Jan 2017
REC opinion
Further Information Favourable Opinion